Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GKOS
stocks logo

GKOS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
129.53M
+22.78%
-0.201
-49.72%
131.93M
+23.69%
-0.184
-16.28%
149.38M
+20.35%
-0.117
-51.26%
Estimates Revision
The market is revising Upward the revenue expectations for Glaukos Corporation (GKOS) for FY2025, with the revenue forecasts being adjusted by 1.96% over the past three months. During the same period, the stock price has changed by 15.87%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.96%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.06%
In Past 3 Month
Stock Price
Go Up
up Image
+15.87%
In Past 3 Month
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 117.30 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 117.30 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
1 Sell
Strong Buy
Current: 108.850
sliders
Low
72.00
Averages
117.30
High
165.00
Current: 108.850
sliders
Low
72.00
Averages
117.30
High
165.00
Citi
Buy
maintain
$110 -> $113
2025-10-30
Reason
Citi
Price Target
$110 -> $113
2025-10-30
maintain
Buy
Reason
Citi raised the firm's price target on Glaukos to $113 from $110 and keeps a Buy rating on the shares.
JPMorgan
NULL -> Overweight
maintain
$110 -> $120
2025-10-30
Reason
JPMorgan
Price Target
$110 -> $120
2025-10-30
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Glaukos to $120 from $110 and keeps an Overweight rating on the shares. The company reported another "beat and raise" quarter, the analyst tells investors in a research note.
Wells Fargo
Overweight
maintain
$120 -> $122
2025-10-30
Reason
Wells Fargo
Price Target
$120 -> $122
2025-10-30
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Glaukos to $122 from $120 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 sales/EPS beat and raised FY25 guidance by $9.5M. Management provided preliminary FY26 sales outlook bracketing consensus. Wells raised its Epioxa and iDose estimates.
BTIG
NULL -> Buy
maintain
$104 -> $116
2025-10-30
Reason
BTIG
Price Target
$104 -> $116
2025-10-30
maintain
NULL -> Buy
Reason
BTIG raised the firm's price target on Glaukos to $116 from $104 and keeps a Buy rating on the shares. The company reported "strong" Q3 as Glaucoma revenue of $110.2M was favorable relative to the firm's estimate, the analyst tells investors in a research note.
Wells Fargo
Larry Biegelsen
Equal Weight -> Overweight
upgrade
$92 -> $120
2025-10-27
Reason
Wells Fargo
Larry Biegelsen
Price Target
$92 -> $120
2025-10-27
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo analyst Larry Biegelsen upgraded Glaukos to Overweight from Equal Weight with a price target of $120, up from $92.
Wells Fargo
Equal Weight -> Overweight
upgrade
$92 -> $120
2025-10-27
Reason
Wells Fargo
Price Target
$92 -> $120
2025-10-27
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Glaukos to Overweight from Equal Weight with a price target of $120, up from $92. Investors are focusing on iDose but the company's Epioxa represents a "significant underappreciated" growth driver, the analyst tells investors in a research note. Wells believes Epioxa gives Glaukos a "sizable, multi-year tailwind" that can move shares materially higher. The firm thinks the company can price Epioxa significantly above its predecessor Photrexa given its broader label and benefits.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Glaukos Corp (GKOS.N) is -197.72, compared to its 5-year average forward P/E of -63.45. For a more detailed relative valuation and DCF analysis to assess Glaukos Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-63.45
Current PE
-197.72
Overvalued PE
-19.32
Undervalued PE
-107.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-529.87
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2391.72
Undervalued EV/EBITDA
-3451.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.09
Current PS
0.00
Overvalued PS
14.33
Undervalued PS
7.85
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 256.76% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 318.02% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 256.76% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

GKOS News & Events

Events Timeline

(ET)
2025-10-30
10:00:12
Glaukos Shares Surge by 27.5%
select
2025-10-29 (ET)
2025-10-29
16:08:35
Glaukos Announces Q3 Earnings Per Share of 16 Cents, Below Consensus Estimate of 26 Cents
select
2025-10-20 (ET)
2025-10-20
12:01:23
Glaukos Experiences a 10.3% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
10-31NASDAQ.COM
Reasons Behind Glaukos Stock Surge of Nearly 14% on Thursday

  • Record Sales Growth: Glaukos achieved a new all-time high in net sales for its third quarter, reaching $133.5 million, a 38% increase year-over-year, primarily driven by glaucoma product sales.

  • Stock Performance: The company's stock surged nearly 14% following the earnings report, contrasting with a 1% decline in the S&P 500, reflecting strong investor confidence.

  • Improved Financials: Glaukos reported a narrower net loss of $9.2 million for the quarter, significantly better than the previous year's loss, and exceeded analyst expectations for revenue and loss per share.

  • Future Guidance: Management raised its full-year 2025 net sales guidance to $490-$495 million and provided preliminary guidance for 2026, estimating net sales of $600-$620 million, indicating continued business momentum.

[object Object]
Preview
4.0
10-31Benzinga
JP Morgan Keeps Overweight Rating on Glaukos and Increases Price Target to $120

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
4.0
10-31Benzinga
Citigroup Reaffirms Buy Rating on Glaukos and Increases Price Target to $113

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

  • Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve their trading outcomes.

  • Market Intelligence: Benzinga Pro is marketed as the fastest and most accurate source of stock market intelligence, aimed at helping traders succeed.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Glaukos Corp (GKOS) stock price today?

The current price of GKOS is 108.85 USD — it has increased 1.29 % in the last trading day.

arrow icon

What is Glaukos Corp (GKOS)'s business?

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

arrow icon

What is the price predicton of GKOS Stock?

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 117.30 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Glaukos Corp (GKOS)'s revenue for the last quarter?

Glaukos Corp revenue for the last quarter amounts to 133.54M USD, increased 38.14 % YoY.

arrow icon

What is Glaukos Corp (GKOS)'s earnings per share (EPS) for the last quarter?

Glaukos Corp. EPS for the last quarter amounts to -0.28 USD, decreased -28.21 % YoY.

arrow icon

What changes have occurred in the market's expectations for Glaukos Corp (GKOS)'s fundamentals?

The market is revising Upward the revenue expectations for Glaukos Corporation (GKOS) for FY2025, with the revenue forecasts being adjusted by 1.96% over the past three months. During the same period, the stock price has changed by 15.87%.
arrow icon

How many employees does Glaukos Corp (GKOS). have?

Glaukos Corp (GKOS) has 995 emplpoyees as of December 05 2025.

arrow icon

What is Glaukos Corp (GKOS) market cap?

Today GKOS has the market capitalization of 6.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free